The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

In addition, Paul Stoffels, who led Galapagos’ transformation into a cell therapy company, will retire from his role within ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...